- Home
- ALIS vs LUNG Comparison
ALIS vs LUNG Comparison
Compare ALIS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALIS | LUNG |
|---|---|---|
| Founded | 2024 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.9M | 97.1M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ALIS | LUNG |
|---|---|---|
| Price | $10.32 | $1.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 40.5K | ★ 272.0K |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | $257.75 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $9.87 | $1.13 |
| 52 Week High | $10.40 | $2.89 |
Technical Indicators
Market Signals| Indicator | ALIS | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 46.94 |
| Support Level | $10.05 | $1.20 |
| Resistance Level | $10.40 | $2.12 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 42.86 | 56.53 |
Price Performance
Historical ComparisonAbout ALIS Calisa Acquisition Corp Ordinary shares
Calisa Acquisition Corp is a blank check company with the purpose of effecting a merger, asset acquisition, stock exchange, stock purchase, reorganization, or similar business combination.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.